Palvella Therapeutics (PVLA) Cash from Investing Activities (2014 - 2026)

Palvella Therapeutics (PVLA) has 12 years of Cash from Investing Activities data on file, last reported at -$55.4 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to -$55.4 million in Q1 2026; TTM through Mar 2026 was -$53.1 million, a 569.36% decrease from a year earlier, with the FY2023 full-year figure at $12.0 million, up 156.52% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$55.4 million, down from $142000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for PVLA reached as high as $11.9 million in Q1 2023 and fell as low as -$55.4 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$4.4 million across 4 years, with a median of $624500.0 in 2022.
• On a YoY basis, Cash from Investing Activities climbed as much as 1662.86% in 2022 and fell as far as 60428.57% in 2022.
• Year by year, Cash from Investing Activities stood at $1.1 million in 2022, then soared by 211.56% to $3.4 million in 2023, then sank by 95.88% to $142000.0 in 2024, then sank by 39142.25% to -$55.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$55.4 million in Q1 2026, $142000.0 in Q3 2024, and $2.2 million in Q2 2024.